Eli Lilly has made a major strategic pivot back into infectious diseases by executing a trio of biotech acquisitions collectively valued at up to $3.8 billion. Funded by the massive financial success of its GLP-1 weight loss and diabetes portfolio, the drugmaker is acquiring Curevo, LimmaTech Biologics, and Vaccine Company (VaxCo). This aggressive diversification effort signals Lilly’s intent to become a major vaccine innovator, aiming to prevent chronic diseases at their source.